Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Edward Agura"'
Autor:
Jennifer R. Brown, Wael Saber, Edwin Alyea, Ronald Sobecks, Uday Popat, Usama Gergis, Asad Bashey, Richard F. Olsson, Saurabh Chhabra, Taiga Nishihori, Baldeep M. Wirk, Jean Yared, Michael R. Grunwald, Jan Cerny, Bipin N. Savani, Amer Beitinjaneh, Sunita Nathan, Edward A. Copelan, Nakhle Saba, Tamila Kindwall-Keller, Attaphol Pawarode, Brian T. Hill, Harry C. Schouten, Mahmoud Aljurf, Ayman Saad, Nilanjan Ghosh, Mohamed A. Kharfan-Dabaja, Melhem Solh, Jean-Yves Cahn, Yoshihiro Inamoto, Gerhard C. Hildebrandt, Ran Reshef, Hillard Lazarus, Ulrike Bacher, Sid Ganguly, Mehdi Hamadani, David I. Marks, Robert Peter Gale, Gregory A. Hale, Minoo Battiwalla, Miguel-Angel Perales, Sergio A. Giralt, Amelia Langston, Stephen Forman, Joseph McGuirk, Jayesh Mehta, Richard Nash, Edward Agura, Joseph Uberti, Steven Devine, Robert Negrin, William Hogan, Joseph Pidala, Oliver Press, Mazyar Shadman, Mohamed L. Sorror, Joseph H. Antin, Virginia O. Volpe, Matthew S. Davids, Zhen-Huan Hu, Kwang Woo Ahn, Haesook T. Kim
Purpose:To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT).Expe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::127fb7c195b7ee0941c57be78c2964de
https://doi.org/10.1158/1078-0432.c.6528513.v1
https://doi.org/10.1158/1078-0432.c.6528513.v1
Autor:
Jennifer R. Brown, Wael Saber, Edwin Alyea, Ronald Sobecks, Uday Popat, Usama Gergis, Asad Bashey, Richard F. Olsson, Saurabh Chhabra, Taiga Nishihori, Baldeep M. Wirk, Jean Yared, Michael R. Grunwald, Jan Cerny, Bipin N. Savani, Amer Beitinjaneh, Sunita Nathan, Edward A. Copelan, Nakhle Saba, Tamila Kindwall-Keller, Attaphol Pawarode, Brian T. Hill, Harry C. Schouten, Mahmoud Aljurf, Ayman Saad, Nilanjan Ghosh, Mohamed A. Kharfan-Dabaja, Melhem Solh, Jean-Yves Cahn, Yoshihiro Inamoto, Gerhard C. Hildebrandt, Ran Reshef, Hillard Lazarus, Ulrike Bacher, Sid Ganguly, Mehdi Hamadani, David I. Marks, Robert Peter Gale, Gregory A. Hale, Minoo Battiwalla, Miguel-Angel Perales, Sergio A. Giralt, Amelia Langston, Stephen Forman, Joseph McGuirk, Jayesh Mehta, Richard Nash, Edward Agura, Joseph Uberti, Steven Devine, Robert Negrin, William Hogan, Joseph Pidala, Oliver Press, Mazyar Shadman, Mohamed L. Sorror, Joseph H. Antin, Virginia O. Volpe, Matthew S. Davids, Zhen-Huan Hu, Kwang Woo Ahn, Haesook T. Kim
Supplementary Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeb0dbb0af3bd7041bdc987cd05fa235
https://doi.org/10.1158/1078-0432.22473450
https://doi.org/10.1158/1078-0432.22473450
Autor:
Mazyar Shadman, Rainer Storb, Thomas R. Chauncey, Brenda M. Sandmaier, Niels Smedegaard Andersen, Dietger Niederwieser, Michael A. Pulsipher, Peter A. McSweeney, Edward Agura, Michael B. Maris, Mohamed L. Sorror, Benedetto Bruno, Judith A. Shizuru, Richard T. Maziarz, Amelia Langston, Parameswaran Hari, David G. Maloney, Barry E. Storer
Publikováno v:
Bone marrow transplantation
Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compa
Autor:
Ronald Sobecks, Melhem Solh, Baldeep Wirk, Joseph P. McGuirk, Zhen-Huan Hu, Kwang Woo Ahn, Yoshihiro Inamoto, Edward Agura, Ulrike Bacher, Miguel-Angel Perales, Usama Gergis, Harry C. Schouten, Joseph Pidala, Amer Beitinjaneh, Amelia Langston, Ran Reshef, Mohamed A. Kharfan-Dabaja, Robert S. Negrin, Saurabh Chhabra, David I. Marks, Virginia O. Volpe, Nilanjan Ghosh, Asad Bashey, Jennifer R. Brown, William J. Hogan, Ayman Saad, Wael Saber, Tamila L. Kindwall-Keller, Minoo Battiwalla, Brian T. Hill, Jan Cerny, Uday R. Popat, Oliver W. Press, Hillard M. Lazarus, Sid Ganguly, Jayesh Mehta, Attaphol Pawarode, Nakhle S. Saba, Taiga Nishihori, Edward A. Copelan, Jean A. Yared, Edwin P. Alyea, Jean-Yves Cahn, Steven M. Devine, Mazyar Shadman, Mahmoud Aljurf, Haesook T. Kim, Mohamed L. Sorror, Michael R. Grunwald, Robert Peter Gale, Richard F. Olsson, Richard A. Nash, Joseph H. Antin, Mehdi Hamadani, Stephen J. Forman, Gregory A. Hale, Bipin N. Savani, Matthew S. Davids, Sunita Nathan, Sergio Giralt, Joseph P. Uberti, Gerhard C. Hildebrandt
Publikováno v:
Clinical Cancer Research, 25(16), 5143-5155. American Association for Cancer Research Inc.
Purpose: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). Ex
Autor:
Sunil Abhyankar, Patrick J. Stiff, Camille N. Abboud, George Chen, John M. Pagel, Zaid S. Al-Kadhimi, Stuart Seropian, Edward Agura, Rajneesh Nath, James M. Foran, Mark S. Berger, Margarida Magalhaes Magalhaes-Silverman, Partow Kebriaei, Michael W. Schuster, Vijay Reddy, Moshe Yair Levy, Hillard M. Lazarus, Sergio Giralt, Boglarka Gyurkocza, Johnnie J. Orozco, Parameswaran Hari, Benjamin Tomlinson, Qing Liang, Mitchell Sabloff, Koen van Besien, Hannah Choe, Mark R. Litzow
Publikováno v:
Blood. 136:42-44
Background: Patients ≥55 years of age with high-risk acute myeloid leukemia (AML) may benefit from an allogeneic hematopoietic cell transplantation (HCT), which is often the only potentially curative therapy available. However, complete remission (
Autor:
Noa Granot, Mohamed L. Sorror, Wolfgang Bethge, Thomas R. Chauncey, Michael B. Maris, Benedetto Bruno, Georg Franke, Boglarka Gyurkocza, William J. Hogan, Julie Asch, Brenda M. Sandmaier, George E. Georges, Amelia Langston, Marco Mielcarek, Rainer Storb, Søren Lykke Petersen, Michael Boyer, Parameswaran Hari, Gitte Olesen, George B. McDonald, Andrew M. Yeager, Jonathan A. Gutman, David G. Maloney, Mary E.D. Flowers, Judith A. Shizuru, Paul J. Martin, Bart L. Scott, Edward Agura, Richard T. Maziarz, H. Joachim Deeg, Jason P. Cooper, Barry E. Storer, Ann E. Woolfrey, Firoozeh Sahebi, Kai Hübel
Publikováno v:
Cooper, J P, Storer, B E, Granot, N, Gyurkocza, B, Sorror, M L, Chauncey, T R, Shizuru, J, Franke, G N, Maris, M B, Boyer, M, Bruno, B, Sahebi, F, Langston, A A, Hari, P, Agura, E D, Petersen, S L, Maziarz, R T, Bethge, W, Asch, J, Gutman, J A, Olesen, G, Yeager, A M, Hübel, K, Hogan, W J, Maloney, D G, Mielcarek, M, Martin, P J, Flowers, M E D, Georges, G E, Woolfrey, A E, Joachim Deeg, H, Scott, B L, McDonald, G B, Storb, R & Sandmaier, B M 2021, ' Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies : Improved outcomes over two decades ', Haematologica, vol. 106, no. 6, pp. 1599-1607 . https://doi.org/10.3324/haematol.2020.248187
Haematologica
Haematologica
We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e697c9bab3e1ad2512b5e50143efe3d
https://pure.au.dk/portal/da/publications/allogeneic-hematopoietic-cell-transplantation-with-nonmyeloablative-conditioning-for-patients-with-hematologic-malignancies(60429385-4bbb-4539-88e1-1b77c148d6c3).html
https://pure.au.dk/portal/da/publications/allogeneic-hematopoietic-cell-transplantation-with-nonmyeloablative-conditioning-for-patients-with-hematologic-malignancies(60429385-4bbb-4539-88e1-1b77c148d6c3).html
Autor:
Andy I. Chen, Veronika Bachanova, Julie Lisano, Tamás Masszi, Jerzy Holowiecki, Auayporn Nademanee, Patrick J. Stiff, Craig H. Moskowitz, Simonetta Viviani, Connie Lee, Teresa McClendon, Muneer H. Abidi, Anna Sureda, Jan Walewski, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 132:2639-2642
The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantatio
Autor:
Parameswaran Hari, Mitchell Sabloff, Boglarka Gyurkocza, Margarida Silverman, Johnnie J. Orozco, Sunil Abhyankar, Camille N. Abboud, Mark S. Berger, Stuart Seropian, John M. Pagel, Edward Agura, Partow Kebriaei, Moshe Yair Levy, George Chen, Rajneesh Nath, Benjamin Tomlinson, James M. Foran, Hannah Choe, Hillard M. Lazarus, Sergio Giralt, Koen van Besien, Michael W. Schuster, Mark R. Litzow, Qing Liang, Patrick J. Stiff, Vijay Reddy, Zaid S. Al-Kadhimi
Publikováno v:
Transplantation and Cellular Therapy. 27:S57-S58
Autor:
Yinghui Wang, Ann S. LaCasce, Andres Forero-Torres, Eric C. Cheung, Jeffrey Matous, Howland E. Crosswell, R. Gregory Bociek, Edward Agura, Ahmed Sawas, Neil C Josephson, Ranjana H. Advani, Caroline Behler, Miguel Islas-Ohlmayer, Stephen M. Ansell, Julie M. Vose, Owen A. O'Connor, Paolo Caimi
Publikováno v:
British Journal of Haematology. 189
Autor:
Qing Liang, George Chen, Hillard M. Lazarus, Boglarka Gyurkocza, Camille N. Abboud, Patrick J. Stiff, Mitchell Sabloff, Edward Agura, Koen van Besien, Mark S. Berger, Mark R. Litzow, Rajneesh Nath, John M. Pagel, Stuart Seropian, Parameswaran Hari, Partow Kebriaei, Margarida Magalhaes Magalhaes-Silverman, Johnnie J. Orozco, Vijay Reddy, James M. Foran, Benjamin Tomlinson, Moshe Yair Levy, Michael W. Schuster, Sunil Abhyankar, Hannah Choe, Zaid S. Al-Kadhimi, Sergio Giralt
Publikováno v:
Blood. 136:30-31
Background: Despite recently approved novel targeted therapies, most patients with high-risk acute myeloid leukemia (AML) still require allogeneic hematopoietic cell transplantation (HCT) to achieve long-term survival. However, older patients with re